Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Evogliptin Monotherapy in T2DM
NCT02946541Phase 3Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of DA5221-B2 in type 2 diabetes mellitus (T2DM), sponsored by Dong-A ST. Started Jul 2013; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02946541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946541.